{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:09Z","timestamp":1740123249486,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2014A030313193"],"award-info":[{"award-number":["2014A030313193"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s10549-017-4259-8","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T05:27:33Z","timestamp":1493184453000},"page":"379-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients"],"prefix":"10.1007","volume":"164","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun-Ai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"4259_CR1","volume-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"WHO","year":"2014","unstructured":"WHO (2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection. World Health Organization, Geneva"},{"key":"4259_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3851\/IMP2552","volume":"18","author":"J Lalezari","year":"2013","unstructured":"Lalezari J, Box T, O\u2019Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-B\u00f3lyai J, Mayers D (2013) IDX184 in combination with pegylated interferon-alpha2a and ribavirin for 2\u00a0weeks in treatment-naive patients with chronic hepatitis C. Antivir Ther 18:755\u2013764. doi:\n                        10.3851\/IMP2552","journal-title":"Antivir Ther"},{"key":"4259_CR3","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2852","author":"Y Liu","year":"2014","unstructured":"Liu Y, Cai Q, Li X, Shao X, Luo Q, Zhang X, Zhao Z (2014) Effect of drug resistance mutations on antiviral agents in HCV patients. Antivir Ther. doi:\n                        10.3851\/IMP2852","journal-title":"Antivir Ther"},{"key":"4259_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3978\/j.issn.2072-1439.2014.03.03","volume":"6","author":"H Zeng","year":"2014","unstructured":"Zeng H, Zheng R, Zhang S, Zou X, Chen W (2014) Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries. J Thorac Dis 6:466\u2013470. doi:\n                        10.3978\/j.issn.2072-1439.2014.03.03","journal-title":"J Thorac Dis"},{"key":"4259_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3978\/j.issn.1000-9604.2015.01.06","volume":"27","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Zeng H, Zhang S, He J (2015) Annual report on status of cancer in China, 2011. Chin J Cancer Res 27:2\u201312. doi:\n                        10.3978\/j.issn.1000-9604.2015.01.06","journal-title":"Chin J Cancer Res"},{"key":"4259_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2014","unstructured":"DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52\u201362. doi:\n                        10.3322\/caac.21203","journal-title":"CA Cancer J Clin"},{"key":"4259_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519\u2013528. doi:\n                        10.7326\/0003-4819-148-7-200804010-00008","journal-title":"Ann Intern Med"},{"key":"4259_CR8","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","volume":"116","author":"D Ennishi","year":"2010","unstructured":"Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116:5119\u20135125. doi:\n                        10.1182\/blood-2010-06-289231","journal-title":"Blood"},{"key":"4259_CR9","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","volume":"57","author":"P Mahale","year":"2012","unstructured":"Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA (2012) Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 57:1177\u20131185. doi:\n                        10.1016\/j.jhep.2012.07.031","journal-title":"J Hepatol"},{"key":"4259_CR10","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"WHO","year":"2015","unstructured":"WHO (2015) Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. World Health Organization, Geneva"},{"key":"4259_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7150\/jca.6231","volume":"4","author":"Y Miura","year":"2013","unstructured":"Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, Takano T (2013) The safety of chemotherapy for breast cancer patients with hepatitis C Virus infection. J Cancer 4:519\u2013523. doi:\n                        10.7150\/jca.6231","journal-title":"J Cancer"},{"key":"4259_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10549-011-1455-9","volume":"127","author":"M Long","year":"2011","unstructured":"Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E (2011) A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 127:705\u2013712. doi:\n                        10.1007\/s10549-011-1455-9","journal-title":"Breast Cancer Res Treat"},{"key":"4259_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","volume":"88","author":"W Yeo","year":"2004","unstructured":"Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ (2004) Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88:209\u2013215. doi:\n                        10.1007\/s10549-004-0725-1","journal-title":"Breast Cancer Res Treat"},{"key":"4259_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3748\/wjg.v19.i6.923","volume":"19","author":"Y Wang","year":"2013","unstructured":"Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y (2013) Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 19:923\u2013930. doi:\n                        10.3748\/wjg.v19.i6.923","journal-title":"World J Gastroenterol"},{"key":"4259_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","volume":"23","author":"F Nicot","year":"2010","unstructured":"Nicot F, Kamar N, Mariam\u00e9 B, Rostaing L, Pasquier C, Izopet J (2010) No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 23:594\u2013601. doi:\n                        10.1111\/j.1432-2277.2009.01025.x","journal-title":"Transpl Int"},{"key":"4259_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","volume":"117","author":"R Eisenberg","year":"2005","unstructured":"Eisenberg R, Looney RJ (2005) The therapeutic potential of anti-CD20 \u201cwhat do B-cells do?\u201d. Clin Immunol 117:207\u2013213. doi:\n                        10.1016\/j.clim.2005.08.006","journal-title":"Clin Immunol"},{"issue":"Suppl 1","key":"4259_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","volume":"11","author":"J Baselga","year":"2006","unstructured":"Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1):4\u201312. doi:\n                        10.1634\/theoncologist.11-90001-4","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"4259_CR18","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.breast.2013.07.029","volume":"22","author":"AC Pinto","year":"2013","unstructured":"Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M (2013) Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 22(Suppl 2):S152\u2013S155. doi:\n                        10.1016\/j.breast.2013.07.029","journal-title":"Breast"},{"key":"4259_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","volume":"62","author":"B Ma","year":"2002","unstructured":"Ma B, Yeo W, Hui P, Ho WM, Johnson PJ (2002) Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer: a retrospective review of Chinese patients and comparison with an historic western series. Radiother Oncol 62:185\u2013189. doi:\n                        10.1016\/S0167-8140(02)00003-8","journal-title":"Radiother Oncol"},{"key":"4259_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","volume":"106","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu H, Tanigawara Y (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the western dose. Cancer Sci 106:497\u2013504. doi:\n                        10.1111\/cas.12647","journal-title":"Cancer Sci"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4259-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T06:21:59Z","timestamp":1498198919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["4259"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4259-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}